New pill for stiff heart condition enters human testing

NCT ID NCT07219511

Recruiting now Disease control Sponsor: Vasa Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called VS-041 in 42 people aged 50 and older who have a type of heart failure where the heart pumps normally but is too stiff (HFpEF). The main goals are to check if the drug is safe and to measure changes in certain blood markers linked to heart health. Participants will take either a low or high dose of VS-041 or a placebo tablet twice daily.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VS-041 (a drug taken as a tablet twice daily)

What this could lead to

If successful, this could point toward a new treatment option for heart failure with preserved ejection fraction (HFpEF), a condition with few approved therapies.

What could go wrong

This is an early Phase 1 trial with only 42 participants, focused on safety and biomarkers—not on whether the drug actually improves symptoms or outcomes. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amavita Health
RECRUITING

North Miami Beach, Florida, 33169, United States
Ash Research Clinic
RECRUITING

Brick, New Jersey, 08724, United States
Broward Research Center
RECRUITING

Pembroke Pines, Florida, 33024, United States
Cardiology and Medicine Clinic
RECRUITING

Little Rock, Arkansas, 72204, United States
Chicago Medical Research
RECRUITING

Hazel Crest, Illinois, 60429, United States
Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Eagle Clinical Research
RECRUITING

Chicago, Illinois, 60621, United States
Erie County Medical Center
RECRUITING

Buffalo, New York, 14215, United States
FOMAT
RECRUITING

Santa Maria, California, 93454, United States
Invivocure LLC
RECRUITING

Van Nuys, California, 91405, United States
Jacksonville Center for Clinical Research
RECRUITING

Jacksonville, Florida, 32216, United States
LinQ Research, LLC
RECRUITING

Tomball, Texas, 77375, United States
Louisiana Heart Center
RECRUITING

Slidell, Louisiana, 70458, United States
Methodist Medical Center of Illinois
NOT_YET_RECRUITING

Peoria, Illinois, 61606, United States
National Institute of Clinical Research
RECRUITING

Huntington Beach, California, 92648, United States
New Generation of Medical Research
RECRUITING

Hialeah, Florida, 33016, United States
Oklahoma Heart Hospital
RECRUITING

Oklahoma City, Oklahoma, 73120, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75231, United States
Wake Forest
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States